Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.
Cancer Res. 2010 Feb 1;70(3):1033-41. doi: 10.1158/0008-5472.CAN-09-2113. Epub 2010 Jan 26.
Microtubule poisons are widely used in cancer treatment, but the factors determining the relative efficacy of different drugs in this class remain obscure. In this study, we identified the NIMA kinase Nek4 in a genetic screen for mediators of the response to Taxol, a chemotherapeutic agent that stabilizes microtubules. After Taxol treatment, Nek4 promoted microtubule outgrowth, whereas Nek4 deficiency impaired G(2)-M arrest and decreased formation of mitotic-like asters. In contrast, Nek4 deficiency sensitized cells to vincristine, which destabilizes microtubules. Therefore, Nek4 deficiency may either antagonize or agonize the effects of microtubule poisons, depending on how they affect microtubule polymerization. Of note, Nek4 gene maps to a commonly deleted locus in non-small cell lung cancer. Thus, Nek4 deletion in this disease may rationalize the use of particular types of microtubule poisons for lung cancer therapy.
微管毒物被广泛应用于癌症治疗,但在该类药物中,决定不同药物相对疗效的因素仍不清楚。在本研究中,我们通过遗传筛选鉴定了 NIMA 激酶 Nek4,该激酶是紫杉醇(一种稳定微管的化疗药物)反应的介质。紫杉醇处理后,Nek4 促进微管生长,而 Nek4 缺陷则损害 G2-M 阻滞并减少有丝分裂样星状体的形成。相反,Nek4 缺陷使细胞对长春新碱(一种破坏微管的药物)敏感。因此,Nek4 缺陷可能拮抗或激动微管毒物的作用,具体取决于它们如何影响微管聚合。值得注意的是,Nek4 基因位于非小细胞肺癌中常见的缺失位点。因此,在该疾病中 Nek4 的缺失可能合理化特定类型的微管毒物用于肺癌治疗。